Patients
From July 2018 to September 2020, 16 pediatric patients with relapsed
and refractory Wilms’ tumor who received doxorubicin hydrochloride
liposome plus irinotecan regimen treated at Sun Yat-Sen University
Cancer Center were collected and included in the analysis. The inclusion
criteria include the following: (1)
Patients with relapsed and refractory Wilms’ tumor aged ≤ 18 years; (2)
Doxorubicin Hydrochloride Liposome plus irinotecan chemotherapy regimen;
(3) The presence of evaluable target lesions; (4) Complete clinical
data. Exclusion criteria was that Patients who had previously received
chemotherapy with doxorubicin-containing liposomes or irinotecan
regimens.
This study was approved by the Sun Yat-Sen University Cancer Center
Ethics Committee.